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quality improvement registry
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and Jack L. Cronenwett, MD,a for the Vascular Study Group of New England, Lebanon, NH; Worcester
and Boston, Mass; and Portland, Me
Objective: Carotid artery stenting (CAS) vs endarterectomy (CEA) remains controversial and has been the topic of recent
randomized controlled trials. The purpose of this study was to compare the practice and outcomes of CAS and CEA in
a real world setting.
Methods: This is a retrospective analysis of 7649 CEA and 430 CAS performed at 17 centers from 2003 to 2010 within
the Vascular Study Group of New England (VSGNE). The primary outcome measures were (1) any in-hospital stroke or
death and (2) any stroke, death, or myocardial infarction (MI). Patients undergoing CEA in conjunction with cardiac
surgery were excluded. Multivariate logistic regression was performed to identify predictors of stroke or death in patients
undergoing CAS.
Results: CEA was performed in 17 centers by 111 surgeons, while CAS was performed in 6 centers by 30 surgeons and 8
interventionalists. Patient characteristics varied by procedure. Patients undergoing CAS had a higher prevalence of
coronary artery disease, congestive heart failure, diabetes, and prior ipsilateral CEA. Embolic protection was used in 97%
of CAS. Shunts were used in 48% and patches in 86% of CEA. The overall in-hospital stroke or death rate was higher
among patients undergoing CAS (2.3% vs 1.1%; P .03). Overall stroke, death, or MI (2.8% CAS vs 2.1% CEA; P .32)
were not different. Asymptomatic patients had similar rates of stroke or death (CAS 0.73% vs CEA 0.89%; P  .78) and
stroke, death, orMI (CAS 1.1% vs CEA 1.8%; P .40). Symptomatic patients undergoing CAS had higher rates of stroke
or death (5.1% vs 1.6%; P .001), and stroke, death, orMI (5.8% vs 2.7%; P .02). Bymultivariate analysis, major stroke
(odds ratio, 4.5; 95% confidence interval [CI], 1.9-10.8), minor stroke (2.7; CI, 1.5-4.8), prior ipsilateral CEA (3.2, CI,
1.7-6.1), age >80 (2.1; CI, 1.3-3.4), hypertension (2.6; CI, 1.0-6.3), and a history of chronic obstructive pulmonary
disease (1.6; CI, 1.0-2.4) were predictors of stroke or death in patients undergoing carotid revascularization.
Conclusions: In our regional vascular surgical practices, the overall outcomes of CAS and CEA are similar for asymptom-
atic patients. However, symptomatic patients treated with CAS are at a higher risk for stroke or death. (J Vasc Surg
2012;56:990-6.)
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iThere are conflicting data regarding the outcomes of
patients undergoing carotid artery stenting (CAS) com-
pared with carotid endarterectomy (CEA) from recent,
large randomized controlled trials. As a consequence, de-
bate surrounds the appropriate use for CAS relative to
CEA. In the 2010 International Carotid Stenting Study
(ICSS), 1713 symptomatic patients from 50 centers in
Europe, Australia, New Zealand, and Canada were ran-
domized to CAS or CEA.1 Thirty-day results showed a
combined stroke, death, myocardial infarction (MI) rate of
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990.4% for CAS, and 4.0% for CEA, P  .006, an effect
rimarily driven by an increased stroke rate of 7.0% for CAS
s 3.3% for CEA.1
In the Carotid Revascularization Endarterectomy vs
tent Trial (CREST), 2502 patients from 117 centers in the
nited States and Canada were randomized to CAS or
EA.2,3 Fifty-three percent of patients were symptomatic
nd 47% were asymptomatic. The 30-day combined stroke,
eath, and MI rate was 5.2% for CAS and 4.5% for CEA,
 .05. However, like ICSS, the stroke rate was higher in
AS patients, 4.1% vs 2.3%. One explanation for the differ-
nces in outcomes is that the populations studied were
ifferent, with ICSS containing only symptomatic patients,
hereas nearly half of the CREST cohort was symptomatic.
While the Center for Medicare and Medicaid Services
CMS) has approved reimbursement for CAS in symptom-
tic “high risk” patients, there currently are no operational
efinitions for the term “high-risk” in the setting of CEA.
everal groups have reported risk factors associated with
troke or death following CEA, with the intent of improv-
ng preoperative risk assessment and patient selection.4-8cross these studies, the most consistent risk factor found
i
a
C
g
c
f
c
s
i
t
i
s
c
t
(
(
T
o
s
v
p
d
p
a
f
t
t
r
t
s
1
w

i
o
i
m
s
i
u
a
.
b
w
i
(
I
p
o
R
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 4 Nolan et al 991to predict stroke or death following CEA has been preop-
erative neurologic symptoms. Other variables associated
with increased operative risk have included emergent oper-
ation,4 renal failure,8 and diabetes.6 While CAS is generally
performed in patients who may be considered high risk for
CEA based on these risk factors, there is no clear evidence
suggesting that the risks with CAS are any lower.
In the setting of this controversy, the purpose of this
study was to analyze the practice and outcomes of CAS
compared with CEA in our region, using the experience
captured in the Vascular Study Group of New England
(VSGNE) database. Specifically, our aims were to perform
a stratified analysis of outcomes across asymptomatic and
symptomatic patients and to develop a risk prediction
model for stroke or death in patients undergoing CAS.
METHODS
Subjects and database. Data from the VSGNE data-
base were used for this analysis. The VSGNE is a regional
cooperative quality improvement initiative developed in
2002 and currently involves over 180 physicians at 28
centers (14 academic, 14 community). The group aims
to study and improve regional outcomes in vascular
surgery and has prospectively collected over 140 detailed
patient demographic, operative, and clinical outcome
variables for CEA since 2003 and CAS since 2005.9
Trained nurses or clinical data abstractors enter data and
research analysts are blinded to patient, surgeon, and
hospital identity. Further details on this registry have
been published previously and are available at http://
www.vascularweb.org/regionalgroups/vsgne.
VSGNE data have been validated for completeness using
biennial audits of discharge claims data from each participat-
ing institution. These audits ensure complete inclusion of all
procedures performed in participating hospitals. In addition,
components for our main outcome measure, postoperative
stroke or death, specifically, ICD-9 codes for CEA (38.12),
and postoperative iatrogenic stroke (997.02), as well as dis-
charge status (alive, dead), have been validated using hospital
administrative claims data.
Validation analyses found initially that 92% of CEAs
that had been performed by participating surgeons during
the specified time interval at all centers had been entered
into the VSGNE database. Data from the remaining 8% of
patients were then retrieved from hospital charts. Thus, this
dataset represents 100% of CEAs performed by VSGNE
members during the specified time period. An audit of cases
with administrative codes for postoperative iatrogenic
stroke revealed that all of these patients were properly
recorded in the VSGNE database. Additionally, three
strokes were reported to VSGNE that had not been coded
in claims data. No postoperative strokes captured in claims
data had been “missed” by the VSGNE data reporting
mechanism.9 We have not formally audited CAS proce-
dures across the VGSNE. However, based on audits for
other procedures (lower extremity bypass and abdominal
aortic aneurysm repair), we have not identified any report- ang bias by procedure. Additionally, we have not identified
ny mortality bias by cases not initially captured.
Our study sample included all patients who underwent
EA (excluding those combined with coronary bypass
rafting) and CAS between 2003 and 2010 at VSGNE
enters. This included 7649 CEA, from 17 centers per-
ormed by 111 surgeons, and 430 CAS performed at 6
enters by 30 vascular surgeons and 8 interventionalists.
Outcome measures. Outcomes were stratified by
ymptomatic status. Symptomatic patients are defined as hav-
ng a neurologic event, including any hemispheric or ocular
ransient ischemic attack,major orminor stroke preceding the
ntervention ipsilateral to the treated lesion. This definition is
imilar to ICSS and CREST, although ICSS lesions were
onsidered symptomatic for up to 1 year preceding interven-
ion and CREST limited to 180 days preop.
The primary outcome measures were (1) any stroke
major or minor, ipsilateral or contralateral) or death; and
2) any stroke, death, orMI. All outcomes were in-hospital.
ransient ischemic attack was not included in the primary
utcome measures but was captured as a secondary mea-
ure. Postoperative major strokes were defined as cortical,
ertebrobasilar, or ocular disability resulting in noninde-
endent living status, or blindness; otherwise strokes were
efined as minor. Neurologists did not routinely examine
atients postop, though this is part of the protocol for CAS
t several of the participating institutions. Myocardial in-
arctions included clinical, electrocardiogram (EKG), and
roponin-only MI. Indications for obtaining postoperative
roponin are institution dependent and variable. No centers
outinely screened all postoperative patients for MI with
roponin. Cranial nerve injuries, a secondary outcomemea-
ure, were deemed permanent by persistence of a deficit at
-year follow-up.
Statistical analysis. Demographic and outcomes data
ere compared using a t-test for continuous variables and
2 with Fisher exact correction (where needed) for categor-
cal or dichotomous variables. To predict in-hospital post-
perative stroke or death after carotid revascularization, we
nitially performed univariate comparisons between our
ain outcome measures and patient level variables (eg,
ymptomatic status, congestive heart failure) as well as
ntraoperative factors (eg, stent architecture, protamine
se), to develop the most robust risk prediction model
vailable. Univariate predictors that were significant at P
10 were then entered into a multivariate model using
ackwards stepwise multivariate logistic regression, which
as used to generate odds ratios and 95% confidence
ntervals for in-hospital stroke or death.
All analyses were performed using Microsoft Excel
Redmond, Wash) and Stata (College Station, Tex). The
nstitutional Review Board at Dartmouth College ap-
roved the use of de-identified data for this study. All tests
f significance were performed at the .05 level.
ESULTS
Patient demographics are shown in Table I. Symptom-
tic status did not differ by procedure, with 34% of CEA
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October 2012992 Nolan et alpatients and 36% of CAS patients exhibiting preoperative
ipsilateral hemispheric or ocular symptoms.However, there
were significant differences in patients selected for CAS
compared with CEA. The proportion of male patients was
higher for CAS than CEA. Additionally, there was a signif-
icantly higher prevalence of tobacco use, coronary artery
disease, congestive heart failure, chronic obstructive pul-
monary disease (COPD), and previous ipsilateral endarter-
ectomy among patients undergoing CAS. Stent patients
were also more likely to be on antiplatelet therapy preop-
eratively and less likely to be on a preoperative -blocker.
Embolic protection was used in 97% of stents, predilation
in 67%, and an open cell stent was used in 82%. Shunts were
used in 47% of CEA, a patch in 86%, general anesthesia in
88%, and a completion duplex in 31%.
The overall rate of stroke or death was significantly
higher in patients undergoing CAS, 2.3%, compared with
CEA, 1.1% (P .028). The overall rate of stroke, death, or
MI (2.8% CAS, 2.1% CEA; P  .319) was not significantly
different. Among asymptomatic patients (CEA  5043;
CAS 273), the rates of stroke or death, and stroke, death,
or MI did not differ between CAS and CEA (Fig 1).
Among symptomatic patients (CEA 2605; CAS 156),
the stroke or death rate was significantly higher in patients
undergoing CAS, 5.1%, compared with CEA, 1.6% (P 
.001). The rate of stroke, death, or MI was also higher for
CAS, 5.8%, compared with CEA, 2.7% (P .022; Fig 2). In
patients who had undergone prior ipsilateral CEA (CEA
172, CAS  144), the rate of stroke or death, and stroke,
death, or MI, did not differ significantly (Fig 3).
Among asymptomatic patients, events were infrequent
for both CAS and CEA, and there were no statistically
Table I. Patient demographics
CEA
(n  7649)
CAS
(n  430) P value
Age 70 69 .13
Male 60% 66% .019
Elective 89% 90% .51
Any symptoms 34% 36% .33
TIA/amaurosis 24% 25% .53
Minor stroke 8% 8% .80
Major stroke 2% 3% .35
Hypertension 88% 88% .73
Any smoking history 80% 85% .014
Coronary artery disease 33% 45% .001
Positive stress test 11% 13% .16
CHF 8% 17% .001
Diabetes 31% 34% .20
COPD 23% 30% .002
Renal insufficiency 6% 8% .070
Prior ipsilateral CEA 2% 33% .001
Antiplatelet therapy 90% 97% .001
Current -blocker therapy 81% 72% .001
Current statin therapy 76% 78% .22
White race 99% 99% .53
CEA, Carotid endarterectomy; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; TIA, transient ischemic attack.significant differences in any of the secondary outcome 0easures–ipsilateral stroke, major stroke, minor stroke,
ransient ischemic attack, MI, death, or permanent cranial
erve injury (Table II, A). Neurologic outcomes among
ymptomatic patients, however, were worse for CAS com-
ared with CEA. This included higher rates of ipsilateral
troke (3.8% vs 1.2%; P  .004), major stroke (2.6% vs
ig 1. Primary outcomes for asymptomatic patients undergoing
arotid artery stent (CAS) and carotid endarterectomy (CEA) in
he Vascular Study Group of New England (VSGNE). (CEA 
043; CAS  273). MI, Myocardial infarction.
ig 2. Primary outcomes for symptomatic patients undergoing
arotid artery stent (CAS) and carotid endarterectomy (CEA) in
he Vascular Study Group of New England (VSGNE). (CEA 
605; CAS  156). MI, Myocardial infarction.
ig 3. Primary outcomes for patients with prior ipsilateral carotid
ndarterectomy (CEA) undergoing carotid artery stent (CAS) and
EA in the Vascular Study Group of New England (VSGNE).
CEA  172; CAS  144). MI, Myocardial infarction..6%; P .005), andminor stroke (2.6% vs 0.8%) (Table II,
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Volume 56, Number 4 Nolan et al 993B). Among patients with a history of prior ipsilateral CEA,
there were no differences in secondary outcomes between
CEA and CAS (Table II, C).
A risk prediction model for stroke or death following
carotid revascularization was developed using multivariate
logistic regression. Factors tested by univariate analysis are
shown in Table III. Factors achieving significance in the
final multivariate model were age80, major stroke, minor
stroke, COPD, hypertension, and a history of prior CEA
(Table IV). Due to colinearity with prior CEA, CAS was
not entered into the multivariate model. The model was
used to develop predicted rates of stroke or death in the
CAS and CEA cohorts given the differences in patient
demographics between these groups. Patients undergoing
CAS had a significantly higher predicted rate of stroke or
death than patients undergoing CEA (2.7% vs 1.8%; P 
.001), reflecting the fact that this was a high-risk popula-
tion. The actual rate of stroke or death among symptomatic
patients undergoing CAS, however, was still significantly
higher than predicted (5.1% vs 2.7%; P  .001; Fig 4).
DISCUSSION
Our study shows that there is an increased risk of stroke
or death in symptomatic patients undergoing CAS com-
pared with CEA in the VSGNE even after accounting for
differences in comorbidities. In contrast, for asymptomatic
patients and patients undergoing prior ipsilateral CEA,
there is no difference in the risk of stroke or death between
CAS or CEA. According to our risk prediction model, age
80, major stroke, minor stroke, COPD, hypertension,
and a history of prior CEA all predicted stroke or death
following carotid revascularization (Table IV).
To determine how the results of our regional practice
Table II. Secondary outcomes
A. Asymptomatic (CEA  5043; CAS  253)
Ipsilateral stroke Major stroke M
CAS 0.4% 0.4%
CEA 0.6% 0.3%
P value .58 .90
B. Symptomatic (CEA  2605; CAS  156)
Any ipsilateral stroke Any major stroke
CAS 3.8% 2.6%
CEA 1.2% 0.6%
P value .004 .005
C. Previous ipsilateral CEA (CEA  172; CAS  144)
Any ipsilateral Stroke Any major stroke
CAS 2.8% 1.4%
CEA 1.7% 1.2%
P value .53 .86
CEA, Carotid endarterectomy; CHF, congestive heart failure; CNI, cranial
Bold indicates significant difference (P  .05).captured in the VSGNE compare with the recent random- tzed controlled trial (RCTs), we compared them with
REST and ICSS.1,2 In both the VSGNE and CREST
ohorts, there was no difference in stroke, death, or MI
ates between CEA and CAS. The rate of stroke, death, or
I in the VSGNE for both CEA (2.1%) and CAS (2.8%)
as about half of that in CREST (4.5% and 5.2%, respec-
stroke TIA MI Death CNI
% 0.5% 0.7% 0.4% 0%
% 0.3% 1.0% 0.2% 0.9%
4 .77 .69 .42 .11
y minor stroke TIA MI Death CNI
2.6% 0.7% 1.3% 1.3% 0%
0.8% 0.6% 1.3% 0.2% 1.1%
.019 .99 .99 .20 .19
y minor stroke TIA MI Death CNI
2.8% 0.6% 2.8% 1.4% 0%
1.7% 0.7% 2.3% 1.2% 0.9%
.53 .9 .77 .86 .26
injury; MI, myocardial infarction; TIA, transient ischemic attack.
able III. Univariate associations with any stroke or
eath after carotid revascularization
OR P value
IA/amaurosis fugax 1.6 .04
inor stroke 2.8 .001
ajor stroke 4.4 .001
ge 80 years 2.2 .001
ge 75 years 0.6 .007
ge 70 years 0.5 .001
ge 65 years 0.6 .08
AS 2.1 .03
revious ipsilateral CEA 3.1 .001
ypertension 2.6 .04
HF 1.9 .03
OPD 1.6 .03
enal insufficiency 1.1 .8
ositive stress test 0.8 .4
tatin use 0.8 .3
rotamine 0.9 .6
lavix 1.1 .6
spirin 0.9 .7
-blocker 1.1 .8
urrent or prior tobacco use 0.9 .8
ale sex 1.1 .8
iabetes 1.0 .9
EA, Carotid endarterectomy; CHF, congestive heart failure; COPD,
hronic obstructive pulmonary disease; OR, odds ratio; TIA, transient
schemic attack.inor
0.5
0.4
.7
An
Anively).2,3 There was a higher proportion of asymptomatic
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October 2012994 Nolan et alpatients in the VSGNE cohort (65% vs 47%). Stroke, death,
or MI in asymptomatic patients from both the VSGNE and
CREST were low and not different between CAS and CEA
(Fig 5). ICSS randomized only symptomatic patients, and
the results are similar to the symptomatic subgroup of
VSGNE patients. Again, the stroke, death, orMI rates were
slightly lower in the symptomatic VSGNE cohort com-
pared with the ICSS cohort for both CEA and CAS.
However, in both the symptomatic VSGNE (CAS 5.8% vs
Table IV. Multivariate predictors of any stroke or death
after carotid revascularization
OR 95% CI P value
Major stroke 4.5 1.9 10.8 .001
Minor stroke 2.7 1.5 4.8 .001
TIA/amaurosis fugax 1.6 1.0 2.5 .064
History of ipsilateral CEA 3.2 1.7 6.1 .001
HTN 2.6 1.0 6.3 .041
Age 80 years 2.1 1.3 3.4 .001
COPD 1.6 1.0 2.4 .035
CEA, Carotid endarterectomy; CI, confidence interval; COPD, chronic
obstructive pulmonary disease; HTN, hypertension; OR, odds ratio; TIA,
transient ischemic attack.
Receiver operator curve  0.6750.
Fig 4. Actual and predicted rates of stroke or death among symp-
tomatic patients. CAS, Carotid artery stent; CEA, carotid
endarterectomy.
Fig 5. Stroke, death, or myocardial infarction (MI) for asymp-
tomatic patients undergoing carotid endarterectomy (CEA) and
carotid artery stent (CAS) in the Vascular Study Group of New
England (VSGNE) and Carotid Revascularization Endarterectomy
vs Stenting Trial (CREST) cohorts.CEA 2.7%; P  .022) and ICSS (CAS 7.4% vs CEA 4.0%; t .006) cohorts, the stroke, death, or MI rates were
ignificantly higher for patients undergoing CAS than
EA.1 In CREST, however, the rate of stroke, death, orMI
id not differ significantly between symptomatic patients
ndergoing CAS (6.7%) and CEA (5.4%). Of note, this was
ue to a higher event rate in patients undergoing CEA–
vent rates in symptomatic patients undergoing CAS were
ery similar in all three cohorts (Fig 6). Although our
esults do not represent randomized control level data, they
emonstrate that in “real world” practice, similar outcomes
n carotid revascularization are observed.
The populations of patients undergoing CAS and CEA
n the VSGNE are significantly different. CAS patients had
ignificantly more medical comorbidities, including con-
estive heart failure, coronary artery disease, and COPD
with renal insufficiency approaching significance). Addi-
ionally, the percentage of patients who had undergone a
revious ipsilateral CEA was much higher in patients un-
ergoing CAS, a finding that differentiates our cohort from
andomized controlled trials where baseline demographics
re well matched through the randomization process.
hough CAS is approved for reimbursement by CMS for
ymptomatic high-risk patients, it is interesting to note that
ymptomatic status did not seem to influence the decision
o perform CAS to the extent that medical comorbidites
nd prior CEA did; that is, CAS was most often used in
symptomatic patients with higher comorbidities or reste-
osis after prior CEA in the VSGNE cohort. There was no
ifference in the percentage of symptomatic patients under-
oing CAS compared with CEA, approximately 35%,
hich also differentiates this cohort from ICSS (100%
ymptomatic) and CREST (53% symptomatic).
In our sample, symptomatic patients undergoingCASdid
onsiderably worse with regard to neurologic outcomes than
atients undergoing CEA. Symptomatic patients treated by
AS had significantly higher rates of any ipsilateral stroke, any
ajor stroke, anyminor stroke, and any stroke or death.These
ndings are consistent with those of ICSS,2 as well as Endar-
ig 6. Stroke, death, or myocardial infarction (MI) for carotid
ndarterectomy (CEA) and carotid artery stent (CAS) in symp-
omatic patients from the Vascular Study Group of New Eng-
and (VSGNE), International Carotid Stenting Study (ICSS),
nd Carotid Revascularization Endarterectomy vs Stenting Trial
CREST) cohorts.erectomy vs Stenting in Patients with Symptomatic Severe
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Volume 56, Number 4 Nolan et al 995Carotid Stenosis study (EVA-3S)10 and the Stent-Supported
Percutaneous Angioplasty of the Carotid Artery vs Endarter-
ectomy study (SPACE),11 though the latter is often criticized
for low usage of embolic protection devices. In fact, the stroke
rate with CAS was higher in CREST, even with a substantial
proportion of asymptomatic patients in the cohort.2 How-
ever, when considering MI in the outcome measure, symp-
tomatic patients had similar outcomes with CAS and CEA.
The inclusion of MI in composite end points for CEA and
CAS has been criticized, and it is questionable to assume that
a major or minor stroke is equivalent to an asymptomatic MI.
It would seem as though the answer is no, at least from a
quality of life standpoint, yet this is the end point traditionally
used inCAS analyses. This is likely due to the fact that patients
undergoing vascular surgery experiencing an asymptomatic
MI based on troponin elevation appear to have lower short-
term and long-term survival.12,13 In a study of patients under-
going aortic or infrainguinal revascularization, or amputation,
those with a troponin leak had a 27-fold increased risk of MI
and a sixfold increased risk of 6-month mortality. Troponin
leak size was positively correlated with mortality rates. Addi-
tionally, life-table analysis demonstrated that these patients
had significantly lower survival up to 2 years after surgery.13
This has been confirmed in vascular patients in follow-up to 5
years as well.12
In contrast to symptomatic patients, the results of CAS
in asymptomatic patients were quite good. Cerebral out-
comes were equivalent to CEA. The finding that asymp-
tomatic patients do considerably better with CAS than
symptomatic patients may bridge the disparity between the
findings reported in CREST and the European trials.
Though operator experience and particularly the use of
embolic protection may also contribute to these differences
in outcomes of patients undergoing CAS,14 it appears clear
in our data that symptomatic status is an important predic-
tor. This is consistent with results from an analysis of the
Nationwide Inpatient Sample showing that symptomatic
patients did disproportionately worse with CAS than
CEA.15
The results of our risk prediction model for stroke or
death following carotid revascularization show that neuro-
logic symptoms, hypertension, COPD, and age 80 pre-
dict poor outcomes. These findings are similar to other
prior risk prediction models for stroke or death following
CEA.16-18 Advanced age and preoperative symptomatic
lesions had similar associations with poor outcomes follow-
ing CEA as in the current analysis.17 The finding that age is
an important independent predictor of outcomes with CAS
has also been previously shown.2,19 These data show that
risk factors often thought to place patients at high risk for
CEA may place them at equally high, or greater risk, for
CAS.
Our study has several limitations. First, our relatively low
event rate, particularly for CAS where the sample size is also
relatively small, may have resulted in a type II error. This may
have limited our ability to identify other predictors of out-
come after CAS such as a benefit from statin use, stent cell
design, types of embolic protection, or operator volume. Also,mall sample size limits our ability to detect a meaningful
olume effect.However, an analysis of event rates in operators
erforming greater than 10 vs less than 10 cases showed no
ifferences in event rates. Second, outcomes in the VSGNE
re self-reported, though some CAS outcomes were neurolo-
ist-adjudicated (per protocol at several institutions). The
vent rates are consistently lower in the VSGNE cohorts
ompared with both CREST and ICSS. It is possible that this
s due to under-reporting of events; however, there is unlikely
o be bias in the reporting of events between procedure (CAS
s CEA) or patient strata (symptomatic vs asymptomatic).
dditionally, neurologists did not examine all patients post-
peratively as in the randomized controlled trials, and there
as no standard protocol for screening forMI, both of which
ay account for slightly lower rates of events than in the
andomized controlled trials. Additionally, all outcomes were
n-hospital and not at 30 days. However, our audit identified
o missed strokes based on claims data indicating that few, if
ny, strokes were missed. Finally, the VSGNE database does
ot contain information about arch and carotid lesion anat-
my or calcification, limiting our ability to make inferences
bout the impact of these factors on outcomes with CAS.
Despite these limitations, our results provide an impor-
ant perspective about the outcomes of CEA vs CAS as
erformed in New England, at both academic and commu-
ity centers. They show that in real-world practice, with
atient selection for each procedure, that neurologic out-
omes with CAS are worse than CEA in symptomatic and
lder patients. The outcomes in asymptomatic patients are
ot significantly different. These data suggest that CASmay
e best suited for asymptomatic, younger patients, al-
hough even larger population studies are required to vali-
ate this.
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